Stealth BioTherapeutics Corp

NasdaqGM:MITO Stok Raporu

Piyasa değeri: US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Reenie McCarthy

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi4.1yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi4.4yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.
Seeking Alpha • Jul 11

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

A clinical-stage biotechnology company, Stealth BioTherapeutics (NASDAQ:MITO) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements.  Company requests an appeal, trading of the company's ADS will be suspended at the opening of business on July 18, 2022. Shares +1.1% after hours
Analiz Makalesi • Dec 31

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Stealth BioTherapeutics Corp ( NASDAQ:MITO ) shareholders should be happy to see the share price up 15% in the last...

CEO

Reenie McCarthy (57 yo)

4.1yrs
Görev süresi

Ms. Irene P. McCarthy, also known as Reenie, J.D., has been President, Chief Executive Officer and Secretory of Stealth BioTherapeutics Corp (formerly known as Stealth BioTherapeutics Inc.) since October 2...

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Irene McCarthy
President 4.4yrsVeri yok0.19%
$ 45.9k
Francis Chen
Independent Non-Employee Director4.4yrsVeri yok0%
$ 0
Kevin McLaughlin
Independent Non-Employee Director4.4yrsVeri yok0%
$ 0
Louis Lange
Independent Director3.3yrsVeri yok0%
$ 0
Lokchung R. Chan
Chairman of the Board4.4yrsVeri yok0%
$ 0
Eve Slater
Director1.9yrsVeri yok0%
$ 0
Edward Owens
Non-Employee Director5.3yrsVeri yok0.11%
$ 25.9k
4.4yrs
Ortalama Görev Süresi
72yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: MITO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2022/11/16 19:37
Gün Sonu Hisse Fiyatı2022/11/15 00:00
Kazançlar2021/12/31
Yıllık Kazançlar2021/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Stealth BioTherapeutics Corp 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
null nullBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI